Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients

The Shuttle Effect : Combination Therapy With Deferiprone and Deferasirox in Transfusion-dependent Thalassemia Patients.

Background: Three iron chelators now available on the market differ in toxicity and organ specificity; evidence on standardized chelation protocol remains inconclusive, but patients with transfusion-dependent beta-thalassemia treated with DFO infusion show significant differences in the limitations of daily activities, physical activity, and quality of life when treated with oral chelator. With licensing of DFP in America, it is reasonable to combine DFP with DFX. Patients find two oral chelators more acceptable than one oral and one injectable. This pilot study rates use of DFP for improving iron excretion profile of deferasirox.

Methods: The investigators enrolled 13 beta-thalassemia patients in China Medical University Children's Hospital in May 2009-October 2011. Five refused to take part in pharmacokinetics; they only participated in iron excretion study. Seven with irregular bowel function were unable to collect feces in the screening period as baseline data. Subjects were randomly assigned and rotated to undergo all treatments (with informed consent): (A) single oral dose of DFX 30 mg/kg once daily, (B) single oral dose of DFP 40 mg/kg twice a day, (C) oral doses of DFX and DFP administered sequentially (DFX 30 mg/kg/d, deferiprone 40 mg/kg/d and deferiprone 40 mg/kg/d at 7-hour intervals). Three-day drug dosage was followed by four-day washout. Collections of urine and stool proceeded 24 hours per day, each analyzed separately. Through a venous catheter, serial blood samples (1 mL/each sampling) were collected in glass tubes containing heparin as anticoagulant at Time 0 (pre-dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 6, 7, 8, 10, 12 and 24 hours after dose; plasma concentrations of DFP and DFX were measured.

Study Overview

• Status: Completed
• Conditions: Beta-thalassemia Major
• Intervention / Treatment: Drug: DFX(Deferasirox); Drug: DFP(Deferiprone)

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• 18 years of age or older
• serum ferritin greater than 2000 ng/mL,
• serum creatinine within normal range for a measuring laboratory
• platelet count exceeding 140000/mm3
• body weight at least 40 Kg
• None had a history of clinical significant of gastrointestinal, hepatic, renal, endocrine, oncologic, infectious, pulmonary or cardiovascular disease

Exclusion Criteria:

• HIV positive, history of immunologic hypersensitivity to any medication
• women pregnant or breast feeding
• drug or alcohol abuse
• patients showed abnormal or irregular bowel function (defined as more than three bowel movements a day or less than one bowel movement every other day)
• receiving warfarin, digoxin, or anti-arrhythmic or antiseizure medication.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: DFX single treatment; a single oral dose of DFX 30 mg/kg once daily, (Exjade®, Novartis Pharmaceuticals Corporation, USA )	Drug: DFX(Deferasirox); Other Names: Exjade®, Novartis Pharmaceuticals Corporation, USA
Active Comparator: DFP single treatment; single oral dose of DFP 40 mg/kg/day twice a day, (Kelfer®, Cipla Ltd., India)	Drug: DFP(Deferiprone); Other Names: Kelfer®, Cipla Ltd., India
Experimental: combination treatment; sequential oral doses of DFX 30 mg/kg/d, DFP 40 mg/kg/d and DFP 40 mg/kg/d (dosing interval: seven hours).	Drug: DFX(Deferasirox); Other Names: Exjade®, Novartis Pharmaceuticals Corporation, USA; Drug: DFP(Deferiprone); Other Names: Kelfer®, Cipla Ltd., India

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
iron excretion from urine and feces by flame atomic absorption spectroscopy	Collections of urine and stool (made 24 hours a day) were analyzed separately.	25-days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
drug concentration in plasma by pharmacokinetics analysis	Through a venous catheter, serial blood samples (1 mL/each sampling) were collected into glass tubes containing heparin as an anticoagulant at time 0 (pre-dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 6, 7, 8, 10, 12 and 24 hours after dosing. Blood samples were centrifuged, with plasma collected and frozen at -20°C until analysis.	25-day

Collaborators and Investigators

• Sponsor: China Medical University Hospital

Study record dates

Study Major Dates

• Study Start: July 1, 2007
• Primary Completion (Actual): July 1, 2008

Study Registration Dates

• First Submitted: July 19, 2014
• First Submitted That Met QC Criteria: July 22, 2014
• First Posted (Estimate): July 23, 2014

Study Record Updates

• Last Update Posted (Estimate): July 23, 2014
• Last Update Submitted That Met QC Criteria: July 22, 2014
• Last Verified: July 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Hematologic Diseases; Genetic Diseases, Inborn; Anemia; Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Hemoglobinopathies; Thalassemia; beta-Thalassemia; Molecular Mechanisms of Pharmacological Action; Chelating Agents; Sequestering Agents; Iron Chelating Agents; Deferasirox; Deferiprone
• Other Study ID Numbers: DMR-096-IRB-037